Waterdrop Inc. (WDH) Q2 2025 Earnings Call Transcript
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 04 2025
0mins
Should l Buy WDH?
Source: SeekingAlpha
Quarterly Revenue CNY 840 million, up 23.9% year-on-year. The increase was driven by the integration of AI with the insurance and healthcare sectors, which improved operational efficiency.
Operating Profit 85.9% year-on-year increase. This was attributed to significant improvements in operational efficiency powered by AI.
Operating Margin Improved by 3.9 percentage points year-over-year, driven by deeper AI integration.
First Year Premium (FYP) CNY 3.2 billion, up 80.2% year-over-year and 53.1% quarter-over-quarter. Growth was driven by technological innovation and AI-driven customer acquisition.
Insurance-related Revenue CNY 740 million, up 28.7% year-over-year and 12.2% quarter-over-quarter. This was supported by deeper AI integration and increased investment in customer acquisition.
Short-term Products FYP CNY 2.43 billion, up 95% year-over-year and 62.1% quarter-over-quarter. Growth was driven by increased investment in customer acquisition and AI capabilities.
Products for People with Preexisting Conditions Quarterly premium of CNY 300 million, a year-on-year increase of 146.6%. This was due to the introduction of innovative insurance products.
Long-term FYP CNY 770 million, a year-on-year increase of 45.4% and sequential increase of 30.5%. Growth was supported by AI tools improving efficiency for online sales consultants and planners.
Digital Clinical Trial Solutions Revenue RMB 27.7 million, a year-on-year increase of 34.2%. Growth was driven by the rapid scale-up and efficiency gains in the digital clinical trial business.
Total Revenue RMB 838 million, representing a year-on-year increase of 23.9% and a quarter-on-quarter increase of 11.2%. Growth was attributed to AI-driven efficiency improvements in customer acquisition, sales, service, and quality control.
Operating Costs and Expenses RMB 741 million, an 18.7% increase year-over-year. The growth rate of costs and expenses was lower than that of revenue, indicating improved operational efficiency.
Sales and Marketing Expenses RMB 199 million, a 26.3% increase year-over-year. This was primarily due to increased marketing expenses for third-party traffic channels.
General and Administrative Expenses RMB 73.4 million, a decrease of 21.9% year-over-year. This was due to tightened operational control and reduced allowance for credit losses.
R&D Expenses RMB 51.9 million, remaining stable year-over-year. Resources were allocated to AI capabilities building.
Net Profit Attributable to Shareholders RMB 140 million, up 58.7% year-over-year. This was supported by robust operational capability and effective synergy among business segments.
Cash Reserves RMB 3.4 billion as of June 30, 2025, with positive operating cash flow, providing a solid foundation for growth and strategic investment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy WDH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on WDH
About WDH
Waterdrop Inc is a holding company principally engaged in the provision of insurance and healthcare service. The Company mainly operates through three segments. The Insurance segment is primarily engaged in the provision of insurance brokerage service, such as health and life insurance products, as well as technical service. The Crowdfunding segment is primarily engaged in the provision of crowdfunding service. The Others segment include online sale of health products, and the provision of digital multichannel marketing solution and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Waterdrop (WDH) Q4 2025 Earnings Call Transcript
See More
Waterdrop Inc. Announces 2025 Financial Results and Dividend
- Significant Revenue Growth: Waterdrop reported net operating revenue of RMB 1.411 billion in Q4 2025, reflecting a 105.5% year-over-year increase, indicating strong momentum in insurance-related income and sustained profitability for the sixteenth consecutive quarter.
- Strong Insurance Performance: In 2025, insurance-related income reached RMB 3.577 billion, a 51.3% year-over-year increase, with Q4 revenue of RMB 1.312 billion up 125.0%, highlighting significant improvements in technical service income that further solidify market positioning.
- Remarkable Medical Crowdfunding Impact: As of December 31, 2025, Waterdrop Medical Crowdfunding raised RMB 72.3 billion for 3.68 million patients, showcasing the company's strong influence in emergency rescue, while upgraded risk control systems effectively mitigated data theft risks.
- Continued Growth in Digital Clinical Trials: Waterdrop's Digital Clinical Trial Solution generated RMB 118.3 million in 2025, a 29.9% year-over-year increase, successfully enrolling 14,555 patients into 1,611 clinical trial programs, demonstrating the company's innovative capabilities in intelligent drug-patient matching technology.
See More
Waterdrop Declares $0.03 Quarterly Dividend per ADS
- Quarterly Dividend Announcement: Waterdrop has declared a quarterly dividend of $0.03 per ADS, consistent with previous distributions, indicating the company's stable cash flow and profitability, which helps bolster investor confidence.
- Payment and Record Dates: The dividend will be payable on May 13 for ordinary shareholders and around May 20 for ADS holders, with a record date of April 24, demonstrating the company's transparency and consistency in its dividend policy.
- Financial Performance Overview: Waterdrop reported a GAAP EPS of $0.01 and revenue of $201.81 million, showing low profitability but indicating revenue growth that highlights the company's market potential in China's InsurTech sector.
- Market Focus: Amid fears of AI disruption, Waterdrop is recognized as a top-rated insurance broker by Seeking Alpha's Quant Rating, reflecting market attention on its future growth and recognition of its business model.
See More
Waterdrop Inc. Reports Significant Revenue Growth in 2025 Financial Results
- Surge in Insurance Revenue: In Q4 2025, Waterdrop's insurance-related income soared by 125% year-over-year, driven by AI models that efficiently manage high concurrency, significantly enhancing competitive positioning.
- Substantial Revenue Growth: The company's net operating revenue for Q4 2025 reached RMB 1.411 billion (approximately USD 201.8 million), marking a 105.5% year-over-year increase, indicating strong performance in the insurance sector.
- Shareholder Return Initiatives: By the end of February 2026, Waterdrop had repurchased approximately 60.7 million ADSs for about USD 118.1 million and plans to distribute a cash dividend of approximately USD 10.8 million, reflecting a strong commitment to shareholder returns.
- Innovation in Digital Clinical Trials: The company secured a national invention patent for China's first intelligent drug-patient matching technology, facilitating collaborations with 224 pharmaceutical companies and contract research organizations, with patient enrollment reaching 1,273, driving a 39.9% year-over-year revenue increase.
See More
Waterdrop Reports Q4 2025 Earnings with Significant Growth
- Earnings Highlights: Waterdrop reported a GAAP EPS of $0.01 for Q4 2025, with revenue reaching $201.81 million, reflecting a robust year-over-year growth of 105.5%, indicating strong potential in the InsurTech sector.
- Insurance Revenue Surge: The quarter saw insurance-related income of RMB 1,310.4 million (approximately $187.4 million), marking a 125.0% increase from the same period in 2024, showcasing the company's enhanced profitability amid rising market demand.
- Crowdfunding Impact: As of December 31, 2025, Waterdrop has facilitated cumulative donations from around 490 million people, totaling RMB 72.3 billion to support 3.68 million patients, highlighting its significant social impact in the medical crowdfunding space.
- Shareholder Returns: The Board approved a cash dividend of $0.03 per ADS and $0.003 per ordinary share, aimed at rewarding shareholders and boosting investor confidence, with the record date set for April 24, 2026.
See More
Waterdrop to Report Q4 and FY 2025 Financial Results on March 25, 2026
- Earnings Report Schedule: Waterdrop Inc. will announce its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2025, before U.S. markets open on March 25, 2026, indicating the company's ongoing growth in the insurance and healthcare sectors.
- Conference Call Timing: The management team will hold a conference call on the same day at 8:00 AM U.S. Eastern Time (8:00 PM Beijing/Hong Kong Time), which is expected to attract significant attention from investors and analysts.
- Dial-in Information: Participants can join the call using various dial-in numbers, including U.S. toll-free and international numbers, ensuring global investor participation and enhancing transparency.
- Webcast and Replay Availability: After the call, telephone replays will be accessible through specified numbers, and live and archived webcasts will be available on the company's investor relations website, further improving information accessibility.
See More
Waterdrop (WDH) Q4 2025 Earnings Call Transcript
See More
Waterdrop Inc. Announces 2025 Financial Results and Dividend
- Significant Revenue Growth: Waterdrop reported net operating revenue of RMB 1.411 billion in Q4 2025, reflecting a 105.5% year-over-year increase, indicating strong momentum in insurance-related income and sustained profitability for the sixteenth consecutive quarter.
- Strong Insurance Performance: In 2025, insurance-related income reached RMB 3.577 billion, a 51.3% year-over-year increase, with Q4 revenue of RMB 1.312 billion up 125.0%, highlighting significant improvements in technical service income that further solidify market positioning.
- Remarkable Medical Crowdfunding Impact: As of December 31, 2025, Waterdrop Medical Crowdfunding raised RMB 72.3 billion for 3.68 million patients, showcasing the company's strong influence in emergency rescue, while upgraded risk control systems effectively mitigated data theft risks.
- Continued Growth in Digital Clinical Trials: Waterdrop's Digital Clinical Trial Solution generated RMB 118.3 million in 2025, a 29.9% year-over-year increase, successfully enrolling 14,555 patients into 1,611 clinical trial programs, demonstrating the company's innovative capabilities in intelligent drug-patient matching technology.
See More
Waterdrop Declares $0.03 Quarterly Dividend per ADS
- Quarterly Dividend Announcement: Waterdrop has declared a quarterly dividend of $0.03 per ADS, consistent with previous distributions, indicating the company's stable cash flow and profitability, which helps bolster investor confidence.
- Payment and Record Dates: The dividend will be payable on May 13 for ordinary shareholders and around May 20 for ADS holders, with a record date of April 24, demonstrating the company's transparency and consistency in its dividend policy.
- Financial Performance Overview: Waterdrop reported a GAAP EPS of $0.01 and revenue of $201.81 million, showing low profitability but indicating revenue growth that highlights the company's market potential in China's InsurTech sector.
- Market Focus: Amid fears of AI disruption, Waterdrop is recognized as a top-rated insurance broker by Seeking Alpha's Quant Rating, reflecting market attention on its future growth and recognition of its business model.
See More
Waterdrop Inc. Reports Significant Revenue Growth in 2025 Financial Results
- Surge in Insurance Revenue: In Q4 2025, Waterdrop's insurance-related income soared by 125% year-over-year, driven by AI models that efficiently manage high concurrency, significantly enhancing competitive positioning.
- Substantial Revenue Growth: The company's net operating revenue for Q4 2025 reached RMB 1.411 billion (approximately USD 201.8 million), marking a 105.5% year-over-year increase, indicating strong performance in the insurance sector.
- Shareholder Return Initiatives: By the end of February 2026, Waterdrop had repurchased approximately 60.7 million ADSs for about USD 118.1 million and plans to distribute a cash dividend of approximately USD 10.8 million, reflecting a strong commitment to shareholder returns.
- Innovation in Digital Clinical Trials: The company secured a national invention patent for China's first intelligent drug-patient matching technology, facilitating collaborations with 224 pharmaceutical companies and contract research organizations, with patient enrollment reaching 1,273, driving a 39.9% year-over-year revenue increase.
See More
Waterdrop Reports Q4 2025 Earnings with Significant Growth
- Earnings Highlights: Waterdrop reported a GAAP EPS of $0.01 for Q4 2025, with revenue reaching $201.81 million, reflecting a robust year-over-year growth of 105.5%, indicating strong potential in the InsurTech sector.
- Insurance Revenue Surge: The quarter saw insurance-related income of RMB 1,310.4 million (approximately $187.4 million), marking a 125.0% increase from the same period in 2024, showcasing the company's enhanced profitability amid rising market demand.
- Crowdfunding Impact: As of December 31, 2025, Waterdrop has facilitated cumulative donations from around 490 million people, totaling RMB 72.3 billion to support 3.68 million patients, highlighting its significant social impact in the medical crowdfunding space.
- Shareholder Returns: The Board approved a cash dividend of $0.03 per ADS and $0.003 per ordinary share, aimed at rewarding shareholders and boosting investor confidence, with the record date set for April 24, 2026.
See More
Waterdrop to Report Q4 and FY 2025 Financial Results on March 25, 2026
- Earnings Report Schedule: Waterdrop Inc. will announce its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2025, before U.S. markets open on March 25, 2026, indicating the company's ongoing growth in the insurance and healthcare sectors.
- Conference Call Timing: The management team will hold a conference call on the same day at 8:00 AM U.S. Eastern Time (8:00 PM Beijing/Hong Kong Time), which is expected to attract significant attention from investors and analysts.
- Dial-in Information: Participants can join the call using various dial-in numbers, including U.S. toll-free and international numbers, ensuring global investor participation and enhancing transparency.
- Webcast and Replay Availability: After the call, telephone replays will be accessible through specified numbers, and live and archived webcasts will be available on the company's investor relations website, further improving information accessibility.
See More
